by New research has revealed promising results for two orally administered glucagon-like peptide 1 receptor agonists (GLP-1RAs) in the treatment of type 2 diabetes mellitus and obesity. The study, published in the journal Metabolism, conducted a systematic review of randomized controlled trials that investigated the safety and efficacy of danuglipron and orforglipron in managing these conditions.
GLP-1RAs have shown potential in maintaining euglycemia and have beneficial effects on cardio-renal health. However, currently available options need to be administered subcutaneously, leading to difficulties for many patients and decreased medication adherence. As obesity is closely linked to type 2 diabetes, there is growing interest in developing orally administered GLP-1RAs.
The study aimed to summarize the existing evidence on the safety and efficacy of danuglipron and orforglipron in the treatment of obesity and type 2 diabetes mellitus. Only randomized controlled trials that compared these small-molecule GLP-1RAs with other antidiabetic medications or placebo in adult patients were included in the review.
The primary outcome of interest was the absolute changes in the percentage of glycated hemoglobin (HbA1c) between the treatment and control groups. Secondary outcomes included differences in body weight, fasting plasma glucose, blood pressure, body mass index, and heart rate.
The safety profiles of danuglipron and orforglipron were also evaluated, looking at adverse events such as constipation, dyspepsia, nausea, hypoglycemia, and events leading to treatment discontinuation.
Preliminary findings showed that danuglipron and orforglipron effectively reduced body weight and improved glycemic control in patients with type 2 diabetes and obesity. The novel GLP-1RAs resulted in significant decreases in HbA1c levels and weight. However, adverse gastrointestinal events such as diarrhea, nausea, constipation, and vomiting were more common in the treatment groups, leading to higher odds of treatment discontinuation.
The safety profiles did not indicate an increased risk of serious adverse reactions or hypoglycemic events with danuglipron and orforglipron. Longitudinal studies are needed to evaluate the long-term efficacy, tolerability, and safety of these treatment options.
These findings highlight the potential of oral GLP-1RAs in managing type 2 diabetes and obesity. By providing an alternative to injections, these medications can improve compliance and patient outcomes. However, the gastrointestinal side effects should be carefully considered, as they may impact patient tolerance and adherence to treatment. Further research is required to fully understand the potential benefits and drawbacks of danuglipron and orforglipron.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
